Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
Public ClinicalTrials.gov record NCT02273960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
Study identification
- NCT ID
- NCT02273960
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- BMS-986004 75 mg IV Drug
- BMS-986004 225 mg IV Drug
- BMS-986004 675 mg IV Drug
- BMS-986004 1500 mg IV Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2014 (Actual)
- Primary completion
- Jan 22, 2018 (Actual)
- Completion
- Jan 22, 2018 (Actual)
- Last update posted
- Jul 16, 2019
2014 – 2018
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ. Of Southern Calif. /Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Columbus Regional Research Institute | Columbus | Georgia | 31904 | — |
| Mass General Hospital | Boston | Massachusetts | 02114 | — |
| Rutgers- Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02273960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2019 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02273960 live on ClinicalTrials.gov.